ImmuCell Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	6.81	3.81	3.76	0.98	5.79	10.19
Cash & Short-Term Investments	6.81	3.81	3.76	0.98	5.79	10.19
Cash Growth	48.12%	1.29%	283.99%	-83.10%	-43.14%	28.18%
Accounts Receivable	2.69	3.42	3.77	2.19	1.76	2.69
Inventory	8.67	9.27	7.11	7.81	6.04	3.09
Other Current Assets	0.68	0.45	0.4	0.49	0.41	0.3
Total Current Assets	18.86	16.94	15.04	11.47	13.99	16.26
Net Property, Plant & Equipment	25.12	25.45	29.91	32.15	30.64	28
Other Intangible Assets	-	-	0.02	0.04	0.06	0.08
Goodwill	0.1	0.1	0.1	0.1	0.1	0.1
Other Long-Term Assets	0.03	0.04	0.03	0.06	0.08	0.03
Total Assets	44.11	42.53	45.1	43.81	44.86	44.47
Accounts Payable	2.2	2.28	2.48	2.12	2	1.61
Current Portion of Long-Term Debt	1.63	1.61	1.5	1.43	1.04	0.81
Current Portion of Leases	0.09	0.09	0.43	0.64	0.03	0.11
Total Current Liabilities	3.91	3.98	4.41	4.2	3.07	2.53
Long-Term Debt	7.07	7.49	9.04	10.54	9.19	8.33
Long-Term Leases	3.99	4.01	4.13	4.08	2.22	1.03
Total Long-Term Liabilities	11.06	11.5	13.17	14.62	11.41	9.35
Total Liabilities	14.97	15.48	17.58	18.82	14.48	11.89
Common Stock	0.91	0.91	0.9	0.78	0.78	0.78
Treasury Stock	-0.19	-0.13	-0.14	-0.14	-0.15	-0.16
Additional Paid-in Capital	41.68	41.48	40.92	36.36	35.98	35.69
Retained Earnings	-13.26	-15.2	-14.16	-12.01	-6.23	-3.74
Shareholders' Equity	29.14	27.06	27.52	24.99	30.38	32.58
Total Liabilities & Equity	44.11	42.53	45.1	43.81	44.86	44.47
Total Debt	12.78	13.19	15.1	16.69	12.48	10.27
Net Cash (Debt)	-5.96	-9.39	-11.34	-15.71	-6.69	-0.09
Net Cash Per Share	-0.66	-1.04	-1.39	-2.03	-0.86	-0.01
Book Value	29.14	27.06	27.52	24.99	30.38	32.58
Book Value Per Share	3.22	3.00	3.37	3.23	3.92	4.29
Tangible Book Value	29.04	26.96	27.4	24.86	30.23	32.41
Tangible Book Value Per Share	3.21	2.99	3.36	3.21	3.90	4.27

SEC Filings: 10-K · 10-Q